TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Trevi Therapeutics ( (TRVI) ).
On December 4, 2025, Trevi Therapeutics announced the appointment of David Hastings as the new Chief Financial Officer, effective January 6, 2026. Hastings brings extensive experience from his previous roles at various biopharmaceutical companies, including Arbutus Biopharma and Incyte Corporation. This strategic hire is expected to strengthen Trevi’s financial leadership, potentially enhancing its market position and operational efficiency.
The most recent analyst rating on (TRVI) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Trevi Therapeutics stock, see the TRVI Stock Forecast page.
Spark’s Take on TRVI Stock
According to Spark, TipRanks’ AI Analyst, TRVI is a Neutral.
Trevi Therapeutics shows promise with significant clinical progress and a strong cash position, essential for sustaining operations in a pre-revenue phase. However, ongoing financial losses and valuation risks temper the outlook. The stock’s technical indicators suggest strong momentum, but investors should be cautious due to potential volatility and financial risks inherent in early-stage biotechnology companies.
To see Spark’s full report on TRVI stock, click here.
More about Trevi Therapeutics
Trevi Therapeutics, Inc. operates in the biopharmaceutical industry, focusing on developing treatments for serious neurological conditions. The company is engaged in the research and development of therapies that address significant unmet medical needs.
Average Trading Volume: 2,183,403
Technical Sentiment Signal: Buy
Current Market Cap: $1.73B
Learn more about TRVI stock on TipRanks’ Stock Analysis page.